← All indications
Puberty, Precocious
Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
Drugs by status
Approved for this indication (5)
Phase 4 trials (2)
Phase 3 trials (2)
Phase 2 trials (6)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (30)
- Abbott
- AbbVie
- Debiopharm
- Ipsen
- Endo Pharmaceuticals
- Tolmar Inc.
- University of Arizona
- University of Washington
- Indiana University
- Rutgers University
- University of Rochester
- University of Chile
- University of Cincinnati
- Orphan Reach
- Louisiana State University
- St. Barnabas Medical Center, Livingston, NJ
- Arnold Palmer Hospital for Children
- Barry J. Reiner, MD, LLC, Baltimore, Maryland
- SRCR, Inc, Bell Gardens, California
- Endocrine Associates of Dallas, Plano, Texas
- Pediatric Endocrine Associates, Atlanta, Georgia
- Alzohaili Medical Consultants, Dearborn, Michigan
- Van Meter Pediatric Endocrinology, Peachtree City, Georgia
- Pennsylvania State University
- Nancy Wright MD P.A., Tallahasse, Florida
- Lynn Health Science Institute
- State University of New York, Buffalo
- Washington University in St. Louis
- Children's National Medical Center
- University of Monterrey, Mexico
Organization Involved with Phase 2 Indications (2)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (2)